Full-Time

Quality Engineer I

Confirmed live in the last 24 hours

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Develops medical devices for vascular conditions

Compensation Overview

$80k - $105k/yr

Entry, Junior

Company Historically Provides H1B Sponsorship

Alameda, CA, USA

Category
QA & Testing
Quality Assurance
Requirements
  • 1+ years of experience in a manufacturing or laboratory environment strongly preferred
  • A Bachelor’s or Master's degree in an engineering or scientific discipline required
  • Clear and concise written and oral communication skills required
Responsibilities
  • Provide valuable input in the design control process and help in developing and launching new products
  • Lead strategic plans for biocompatibility and sterilization for upcoming products
  • Independently provide knowledge of Penumbra Quality Management System as it pertains to sustaining manufacturing operations as well as dealing with supplier quality and developing new products
  • Identify and drive areas of opportunity for process improvement, yield improvement, and cycle time reduction
  • Determine root-cause of in-process quality assurance issues
  • Experience on production lines manufacturing high performing products
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures
  • Ensure other members of the department follow the QMS, regulations, standards and procedures
  • Perform other activities requiring knowledge of principles and techniques commonly employed in the specific area of projects.
Desired Qualifications
  • Proven ability to thrive in a fast-paced work environment where navigating grey areas is a welcomed challenge preferred
  • A passion for working in collaborative and dynamic teams with feedback-rich culture preferred

Penumbra Inc. specializes in creating medical devices for treating neurovascular and peripheral vascular conditions. Their products, such as the Penumbra System and Indigo System, are designed to assist healthcare professionals in addressing issues like stroke and other vascular diseases. These devices work by providing advanced tools for interventions in neurology and vascular surgery, allowing for effective treatment options. Unlike many competitors, Penumbra focuses on a specific range of specialized devices and emphasizes continuous research and development to enhance their offerings. The company's goal is to deliver high-quality medical solutions that meet the needs of healthcare providers and improve patient outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption enhances precision in stroke detection, complementing Penumbra's devices.
  • Telemedicine growth creates opportunities for integrating Penumbra's devices with digital health platforms.
  • Global demand for minimally invasive procedures boosts Penumbra's device market potential.

What critics are saying

  • Emerging competitors in neurovascular and peripheral vascular markets threaten Penumbra's market share.
  • Don Kassing's retirement may lead to a temporary gap in strategic guidance.
  • Expansion in Costa Rica could face operational challenges and increased costs.

What makes Penumbra Inc unique

  • Penumbra specializes in innovative devices for neurovascular and peripheral vascular conditions.
  • The company offers a broad portfolio, including the Penumbra System and Indigo System.
  • Penumbra's focus on thrombectomy positions it as a leader in clot removal technologies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Apr 3rd, 2025
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release And Conference Call For April 23, 2025

ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life

Penumbrainc
Mar 17th, 2025
Latest Data on Penumbra's CAVT Technology to Be Presented at SIR 2025: STRIDE, STRIKE-PE, and More

Latest data on Penumbra's CAVT technology to be presented at SIR 2025: STRIDE, STRIKE-PE, and more.

Neuro News International
Feb 28th, 2025
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access

Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.

Penumbrainc
Feb 27th, 2025
Penumbra Launches ACCESS25[TM] Delivery Microcatheter Designed for Aneurysm Access and Delivery of Elevated Clinical Benefits

Penumbra recently launched the ACCESS25 Delivery Microcatheter, a single lumen medical device designed to aid physicians in accessing the neurovasculature for the delivery of Penumbra's advanced .020" coil platform.

PR Newswire
Feb 21st, 2025
Penumbra, Inc. Announces Don Kassing Will Retire From Board Of Directors

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University